Back to resultsA Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (EPO-PRETAR)
Primary Purpose
Myelodysplastic Syndromes
Status
Recruiting
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
EPREX
Sponsored by
About this trial
This is an interventional treatment trial for Myelodysplastic Syndromes focused on measuring myelodysplastic syndrome, erythropoetin
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- MDS according to WHO 2016 criteria, with low or int 1 classical IPSS
- Non-RBC transfusion dependent anemia
- Hb level between 9 and 10.5g/dl (at the center's lab)
- Hb level should be at least 1g/dl higher than the Hb threshold chosen to start RBC transfusions based on age, comorbidities and predicted clinical tolerance of anemia (this transfusion threshold should be chosen between 8 and 9g/dl)
- Serum EPO level <500U/l
- No other cause of anemia (including iron deficiency, vitamin B12 or B9 deficiency, hemolysis, hypothyroidism….)
- Performance status <=2
Exclusion Criteria:
- Higher risk MDS (IPSS intermediate-2 or high)
- Del 5q
- Baseline Hemoglobin level > 10.5 g/dl or <9g/dl
- Transfusion threshold (based on age , comorbidities…) >9g/dl
- Transfusion threshold less than 1 g/dl below baseline Hb level
- RBC transfusion dependence. Patients may have received only one transfusion series for MDS prior to inclusion
- CMML , if >10 % BM blasts or WBC>13.000/mm3
- Uncontrolled hypertension
- Uncontrolled cardiovascular disease including angina pectoris or cardiac failure
- Renal failure: Creatinine clearance<40ml/min (using MDRD formula)
- Pregnancy (positive bettaHCG) or nursing
Sites / Locations
- Chu Amiens
- CH Angers
- CH Avignon
- Centre Hospitalier de La Cote Basque
- Hopital Nord Franche-Comté
- CHU de Besançon
- Hopital Avicenne
- Hôpital Morvan
- CHU de Caen
- CH de Sevigné
- CH de Cholet
- CHU Estaing
- CHSF Gilles de Corbeil
- Hôpital Henri-Mondor
- CHU de Grenoble
- Centre Hospitalier du Mans
- Clinique Victor HugoRecruiting
- Hopital Saint-Vincent de Paul
- CHRU Limoges
- Centre Hospitalier Lyon Sud
- IPC
- Centre Hospitalier du Mont de Marsan
- CHU de Nantes
- CHU de Nice
- Hopital St Louis T4
- Centre Hospitalier Joffre-Perpignan
- Sophie Dimicoli-Salazar
- CHU de Poitiers
- CHR d'AnnecyRecruiting
- CH de Périgueux
- CHRU de Reims
- CHU Pontchaillou
- Centre Henri Becquerel
- CH Saint Nazaire
- Centre Hospitalier Universitaire de STRASBOURG
- IUCT Oncopole
- CH de TroyesRecruiting
- CH ValenceRecruiting
- CHU Brabois
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Early onset arm
Delayed onset arm
Arm Description
Intervention: early onset of Eprex60000 IU/week , at patient inclusion
Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
Outcomes
Primary Outcome Measures
Time to RBC transfusion dependence in non RBC transfusion dependent lower risk MDS patients with anemia with early (at inclusion of the patient) versus delayed onset,( at the threshold chosen for RBC transfusion) of EPO ALFA
RBC transfusion dependence will be defined by requirement of at least transfusions of 2 PRBC within an interval of less than 8 weeks, given for Hb <8g/dl or <9g/dl according to comorbidities and in the absence of other cause of anemia (bleeding, surgery…), taking into account only transfusions given at least 12 weeks after onset of treatment with EPO ALFA.
Secondary Outcome Measures
Erythroid response (according to IWG 2006 criteria)
Erythroid response (according to IWG 2006 criteria) after 12 weeks of EPO ALFA treatment
response duration to EPO ALFA
response duration to EPO ALFA measured from the date of enrollment until failure
Overall survival
Overall survival measured from the date of enrollment to death or the date of last contact
Full Information
NCT ID
NCT03223961
First Posted
July 11, 2017
Last Updated
December 1, 2020
Sponsor
Groupe Francophone des Myelodysplasies
1. Study Identification
Unique Protocol Identification Number
NCT03223961
Brief Title
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Acronym
EPO-PRETAR
Official Title
A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Recruiting
Study Start Date
March 26, 2018 (Actual)
Primary Completion Date
May 16, 2022 (Anticipated)
Study Completion Date
May 16, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Groupe Francophone des Myelodysplasies
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is an open-label, randomized, multicenter, phase III study
Patients with baseline Hb comprised between 9 and 10.5g/dl will be randomized to receive EPO Alfa 60000 UI/week for at least 12 weeks:
Either at diagnosis Or
at the Hb threshold chosen for RBC transfusions (must be < 9g/dl)
Detailed Description
in this trial we will compare the early introduction of EPO alfa to the delayed introduction in lower risk MDS with non RBC transfusion dependent anemia.
At enrollment patients will be randomised in the 2 arms (early and delayed start of EPO alfa).
Treatment Regimen Epoetin alfa 60000 UI/week for at least 12 weeks
Early onset arm: early onset of EPO ALFA 60000 IU/week , at patient inclusion
Delayed onset arm: late introduction of EPO ALFA 60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myelodysplastic Syndromes
Keywords
myelodysplastic syndrome, erythropoetin
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
randomazed study
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
124 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Early onset arm
Arm Type
Experimental
Arm Description
Intervention: early onset of Eprex60000 IU/week , at patient inclusion
Arm Title
Delayed onset arm
Arm Type
Experimental
Arm Description
Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
Intervention Type
Drug
Intervention Name(s)
EPREX
Other Intervention Name(s)
Epoetin alfa
Intervention Description
60 000 U/week for at least 12 weeks
Primary Outcome Measure Information:
Title
Time to RBC transfusion dependence in non RBC transfusion dependent lower risk MDS patients with anemia with early (at inclusion of the patient) versus delayed onset,( at the threshold chosen for RBC transfusion) of EPO ALFA
Description
RBC transfusion dependence will be defined by requirement of at least transfusions of 2 PRBC within an interval of less than 8 weeks, given for Hb <8g/dl or <9g/dl according to comorbidities and in the absence of other cause of anemia (bleeding, surgery…), taking into account only transfusions given at least 12 weeks after onset of treatment with EPO ALFA.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Erythroid response (according to IWG 2006 criteria)
Description
Erythroid response (according to IWG 2006 criteria) after 12 weeks of EPO ALFA treatment
Time Frame
12 weeks
Title
response duration to EPO ALFA
Description
response duration to EPO ALFA measured from the date of enrollment until failure
Time Frame
4 years
Title
Overall survival
Description
Overall survival measured from the date of enrollment to death or the date of last contact
Time Frame
4 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years
MDS according to WHO 2016 criteria, with low or int 1 classical IPSS
Non-RBC transfusion dependent anemia
Hb level between 9 and 10.5g/dl (at the center's lab)
Hb level should be at least 1g/dl higher than the Hb threshold chosen to start RBC transfusions based on age, comorbidities and predicted clinical tolerance of anemia (this transfusion threshold should be chosen between 8 and 9g/dl)
Serum EPO level <500U/l
No other cause of anemia (including iron deficiency, vitamin B12 or B9 deficiency, hemolysis, hypothyroidism….)
Performance status <=2
Exclusion Criteria:
Higher risk MDS (IPSS intermediate-2 or high)
Del 5q
Baseline Hemoglobin level > 10.5 g/dl or <9g/dl
Transfusion threshold (based on age , comorbidities…) >9g/dl
Transfusion threshold less than 1 g/dl below baseline Hb level
RBC transfusion dependence. Patients may have received only one transfusion series for MDS prior to inclusion
CMML , if >10 % BM blasts or WBC>13.000/mm3
Uncontrolled hypertension
Uncontrolled cardiovascular disease including angina pectoris or cardiac failure
Renal failure: Creatinine clearance<40ml/min (using MDRD formula)
Pregnancy (positive bettaHCG) or nursing
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sophie Park, Prof
Phone
+33 (0)4 76 76 62 77
Email
spark@chu-grenoble.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Fatiha Chermat, CRA
Phone
+33 (0)1 71 20 70 59
Email
fatiha.chermat-ext@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sophie Park, Prof
Organizational Affiliation
University Hospital, Grenoble
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chu Amiens
City
Amiens
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Berengere gruson, MD
Phone
+33322455985
Email
gruson.berengere@chu-amiens.fr
First Name & Middle Initial & Last Name & Degree
Berengere Gruson, MD
Facility Name
CH Angers
City
Angers
ZIP/Postal Code
49 000
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sylvain THEPOT
Phone
+33 2 41 35 44 66
Email
sylvain.thepot@chu-angers.fr
First Name & Middle Initial & Last Name & Degree
Sylvain Tepot, MD
Facility Name
CH Avignon
City
Avignon
ZIP/Postal Code
84000
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bohrane Slama, MD
Phone
0432753132
Email
bslama@ch-avignon.fr
First Name & Middle Initial & Last Name & Degree
Bohrane Slama, MD
Facility Name
Centre Hospitalier de La Cote Basque
City
Bayonne
ZIP/Postal Code
64100
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Banos, MD
Phone
033559443832
Email
abanos@ch-cotebasque.fr
First Name & Middle Initial & Last Name & Degree
Anne Banos, MD
Facility Name
Hopital Nord Franche-Comté
City
Belfort
ZIP/Postal Code
90015
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elena-Catalina ENACHE, MD
Phone
0384982322
Email
elena.catalina.enache@hnfc.fr
First Name & Middle Initial & Last Name & Degree
Elena-Catalina ENACHE, MD
Facility Name
CHU de Besançon
City
Besançon
ZIP/Postal Code
25030
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ana BERCEANU, MD
Phone
0381668351
Email
aberceanu@chu-besancon.fr
First Name & Middle Initial & Last Name & Degree
Ana BERCEANU, MD
Facility Name
Hopital Avicenne
City
Bobigny
ZIP/Postal Code
9300
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thorsten Braun, MD
Phone
+33148957057
Email
thorsten.braun@aphp.fr
First Name & Middle Initial & Last Name & Degree
Thorsten Braun, MD
Facility Name
Hôpital Morvan
City
Brest
ZIP/Postal Code
29609
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Berthou, Prof
Phone
+33298223504
Email
christianberthou@wanadoo.fr
First Name & Middle Initial & Last Name & Degree
Christian Berthou, Prof
Facility Name
CHU de Caen
City
Caen
ZIP/Postal Code
14033
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stéphane Cheze, MD
Phone
+33231272360
Email
cheze-s@chu-caen.fr
First Name & Middle Initial & Last Name & Degree
Stéphane Cheze, MD
Facility Name
CH de Sevigné
City
Cesson
ZIP/Postal Code
35510
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Violaine DONCKER, MD
Phone
0223210550
Email
violainedoncker@gmail.com
First Name & Middle Initial & Last Name & Degree
Anne Violaine DONCKER, MD
Facility Name
CH de Cholet
City
Cholet
ZIP/Postal Code
49325
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anaise BLOUET, MD
Phone
0241496807
Email
anaise.blouet@ch-cholet.fr
First Name & Middle Initial & Last Name & Degree
Anaise BLOUET, MD
Facility Name
CHU Estaing
City
Clermont-Ferrand
ZIP/Postal Code
63000
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benoit De RENZIS, MD
Phone
+33 4 73 75 00 66
Email
bderenzis@chu-clermontferrand.fr
First Name & Middle Initial & Last Name & Degree
Benoit De RENZIS, MD
Facility Name
CHSF Gilles de Corbeil
City
Corbeil-Essonnes
ZIP/Postal Code
91100
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Célia Salanoubat, MD
Phone
+33160903178
Email
celia.salanoubat@ch-sud-francilien.fr
First Name & Middle Initial & Last Name & Degree
Célia Salanoubat, MD
Facility Name
Hôpital Henri-Mondor
City
Créteil
ZIP/Postal Code
94010
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea TOMA, MD
Phone
0149812057
Email
andrea.toma@aphp.fr
First Name & Middle Initial & Last Name & Degree
Andrea TOMA, MD
Facility Name
CHU de Grenoble
City
Grenoble
ZIP/Postal Code
38043
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophie Park, MD, PHD
Phone
+33 4 76 76 62 77
Email
spark@chu-grenoble.fr
First Name & Middle Initial & Last Name & Degree
Sophie Park, MD, PHD
Facility Name
Centre Hospitalier du Mans
City
Le Mans cedex
ZIP/Postal Code
72000
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kamel Laribi, MD
Phone
+33243434361
Email
klaribi@ch-lemans.fr
First Name & Middle Initial & Last Name & Degree
Kamel Laribi, MD
Facility Name
Clinique Victor Hugo
City
Le Mans
ZIP/Postal Code
72000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katell LE DU, MD
Phone
0243479493
Email
essaisledu@i-l-c.fr
First Name & Middle Initial & Last Name & Degree
Katell LE DU, MD
Facility Name
Hopital Saint-Vincent de Paul
City
Lille
ZIP/Postal Code
59160
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Rose, MD
Phone
+33 20874532
Email
rose.christian@ghicl.net
First Name & Middle Initial & Last Name & Degree
Christian Rose, Prof
Facility Name
CHRU Limoges
City
Limoges
ZIP/Postal Code
87042
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie-Pierre Gourin, MD
Phone
+33555056642
Email
marie-pierre.gourin@chu-limoges.fr
First Name & Middle Initial & Last Name & Degree
Marie-Pierre Gourin, MD
Facility Name
Centre Hospitalier Lyon Sud
City
Lyon
ZIP/Postal Code
69495
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric Wattel, MD, PHD
Phone
+33 4 72 11 74 01
Email
wattel@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
Eric Wattel, MD, PHD
Facility Name
IPC
City
Marseille
ZIP/Postal Code
13273
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Norbert Vey, prof
Phone
033 4 91 22 36 67
Email
veyn@ipc.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Norbert Vey, prof
Facility Name
Centre Hospitalier du Mont de Marsan
City
Mont-de-Marsan
ZIP/Postal Code
40000
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
REZA TABREZI, MD
Phone
05 58 05 11 62
Email
reza.tabrizi@ch-mdm.fr
First Name & Middle Initial & Last Name & Degree
REZA TABREZI, MD
Facility Name
CHU de Nantes
City
Nantes
ZIP/Postal Code
44093
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre Peterlin, MD
Phone
+33 2 40 08 32 77
Email
pierre.peterlin@chu-nantes.fr
First Name & Middle Initial & Last Name & Degree
Pierre Peterlin, MD
Facility Name
CHU de Nice
City
Nice
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Cluzeau, MD
Phone
+33492035844
Email
cluzeau.t@chu-nice.fr
First Name & Middle Initial & Last Name & Degree
Thomas Cluzeau, MD
Facility Name
Hopital St Louis T4
City
Paris
ZIP/Postal Code
75475
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre Fenaux, PHD
Phone
+33 171207018
Email
pierre.fenaux@aphp.fr
First Name & Middle Initial & Last Name & Degree
Pierre Fenaux, prof
Facility Name
Centre Hospitalier Joffre-Perpignan
City
Perpignan
ZIP/Postal Code
66046
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurence Sanhes, MD
Phone
+33468616448
Email
laurence.sanhes@ch-perpignan.fr
First Name & Middle Initial & Last Name & Degree
Laurence Sanhes, MD
Facility Name
Sophie Dimicoli-Salazar
City
Pessac
ZIP/Postal Code
33604
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophie Dimicoli-Salazar, MD
Phone
+33557656511
Email
sophie.dimicoli-salazar@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Sophie Dimicoli-Salazar, MD
Facility Name
CHU de Poitiers
City
Poitiers
ZIP/Postal Code
86021
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jose Miguel Torregrosa Diaz, MD
Phone
+33 5 48 44 30 29
Email
jose-miguel.torregrosa-diaz@chu-poitiers.fr
First Name & Middle Initial & Last Name & Degree
Jose Miguel Torregrosa Diaz, MD
Facility Name
CHR d'Annecy
City
Pringy
ZIP/Postal Code
74374
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pascale Cony-Makhoul, MD
Phone
+33450636608
Email
pconymakhoul@ch-annecy.fr
First Name & Middle Initial & Last Name & Degree
Pascale Cony-Makhoul, MD
Facility Name
CH de Périgueux
City
Périgueux
ZIP/Postal Code
24019
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marius MOLDOVAN, MD
Phone
0553452585
First Name & Middle Initial & Last Name & Degree
Marius MOLDOVAN, MD
Facility Name
CHRU de Reims
City
Reims
ZIP/Postal Code
51092
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chantal HIMBERLIN, MD
Phone
003326783644
Email
chimberlin@chu-reims.fr
First Name & Middle Initial & Last Name & Degree
Chantal HIMBERLIN, MD
Facility Name
CHU Pontchaillou
City
Rennes
ZIP/Postal Code
35033
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stanislas Nimubona, MD
Phone
33299289521
Email
stanislas.nimubona@chu-rennes.fr
First Name & Middle Initial & Last Name & Degree
Stanislas Nimubona, MD
Facility Name
Centre Henri Becquerel
City
Rouen
ZIP/Postal Code
76038
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aspasia Stamatoulas, MD
Phone
+33 232082288
Email
aspasia.stamatoullas@chb.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Aspasia Stamatoullas, MD
Facility Name
CH Saint Nazaire
City
Saint-Nazaire
ZIP/Postal Code
44600
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elsa LESTANG, MD
Phone
0272278306
Email
e.lestang@ch-saintnazaire.fr
First Name & Middle Initial & Last Name & Degree
Elsa LESTANG, MD
Facility Name
Centre Hospitalier Universitaire de STRASBOURG
City
Strasbourg
ZIP/Postal Code
67098
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shanti NATAJARAN-AME, MD
Phone
00 33 3 88 12 76 70
Email
shanti.ame@chru-strasbourg.fr
First Name & Middle Initial & Last Name & Degree
Shanti NATAJARAN-AME, MD
Facility Name
IUCT Oncopole
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Odile Beyne-Rauzy, Prof
Phone
+33531156264
Email
beynerauzy.odile@iuct-oncopole.fr
First Name & Middle Initial & Last Name & Degree
Odile Beyne-Rauzy, Prof
Facility Name
CH de Troyes
City
Troyes
ZIP/Postal Code
10003
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nadia ALI AMAR, MD
Phone
0325494721
Email
nadia.aliammar@ch-troyes.fr
First Name & Middle Initial & Last Name & Degree
Nadia ALI AMAR, MD
Facility Name
CH Valence
City
Valence
ZIP/Postal Code
26953
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jixing LIU, MD
Phone
0475757566
Email
jliu@ch-valence.fr
First Name & Middle Initial & Last Name & Degree
Jixing LIU, MD
Facility Name
CHU Brabois
City
Vandœuvre-lès-Nancy
ZIP/Postal Code
54511
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Agnès Guerci-Bresler, MD
Phone
+33383153281
Email
a.guerci@chru-nancy.fr
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
We'll reach out to this number within 24 hrs